Multimodal Imaging Response after the Singular or Combination Treatments of Vascular Endothelial Growth Factor Inhibitor and Immune Checkpoint Inhibitor-Reference-Cited by-同舟云学术

Multimodal Imaging Response after the Singular or Combination Treatments of Vascular Endothelial Growth Factor Inhibitor and Immune Checkpoint Inhibitor

Published:2022-08-17 Issue:10 Volume:19 Page:3664-3672
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Ren Yanqiao¹²^ORCID,Pan Feng¹²,Kan Xuefeng¹²,Wang Jiazheng³,Han Ping¹²,Yan Jingjie⁴⁵,Li Lingli¹²,Sun Peng³,Liu Chao-Yang⁴,Bao Qingjia⁴,Yang Lian¹²,Zheng Chuansheng¹²

Affiliation:

1. Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

2. Hubei Key Laboratory of Molecular Imaging, Wuhan 430022, China

3. Clinical & Technical Solutions, Philips Healthcare, Beijing 100600, China

4. State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, Wuhan Institute of Physics and Mathmatics, Innovation Academy for Precision Measurement Science and Technology, Wuhan 430071, China

5. Wuhan National Laboratory for Optoelectronics, Huazhong University of Science and Technology, Wuhan 430074, China

Funder

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.2c00474

Reference33 articles.

1. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma

2. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

3. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study

4. Sorafenib in Advanced Hepatocellular Carcinoma

5. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a Novel CD8⁺ T Cell-Associated Signature for Prognostic Assessment in Hepatocellular Carcinoma;Cancer Control;2024-01

2. Multiparametric chemical exchange saturation transfer MRI detects metabolic changes in breast cancer following immunotherapy;Journal of Translational Medicine;2023-08-28